The Effect of Irbesartan on the Development of Diabetic Nephropathy in Patients with Type 2 Diabetes
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Introduction Microalbuminuria and hypertension are risk factors for the development of diabetic nephropathy. Blockade of the renin-angiotensin system reduces progression to diabetic nephropathy in type 1 diabetic patients, whereas similar data are lacking for hypertensive type 2 diabetic subjects. We evaluated the renoprotective effect of an angiotensin II receptor antagonist, irbesartan, in hypertensive type 2 diabetic patients with microalbuminuria. Material and methods Five hundred and ninety hypertensive type 2 diabetic patients with microalbuminuria were enrolled in this multinational, randomised, double-blind, placebo-controlled study of irbesartan 150 mg/daily or 300 mg/daily or matching placebo for two years. The primary outcome was time to progression to diabetic nephropathy, defined as a persistent overnight albuminuria > 200 micrograms/min and at least a 30 per cent increase from baseline. Results Baseline characteristics in the three groups were similar. Ten patients (5.2 per cent) receiving irbesartan 300 mg and 19 patients (9.7 per cent) receiving irbesartan 150 mg daily reached the primary end point, as compared to 30 (14.9 per cent) patients on placebo (hazard ratio 0.30 [95 per cent confidence interval 0.14 to 0.61], p Discussions Irbesartan is renoprotective independently of its blood pressure lowering effect in type 2 diabetic subjects with microalbuminuria. It is safe and well tolerated.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Antihypertensive therapy reduces the risk of albuminuria (67)(68)(69)(70), and among people with type 1 or 2 diabetes with established CKD (eGFR <60 mL/min/1.73m 2 and UACR $300 mg/g creatinine), ACE inhibitor or ARB therapy reduces the risk of progression to ESKD (71)(72)(73)(74)(75)(76)(77)(78)(79)(80).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [77]
In the citing paper
“In the setting of lower levels of albuminuria (30-299 mg/g creatinine), ACE inhibitor or ARB therapy at maximum tolerated doses in trials has reduced progression to more advanced albuminuria ($300 mg/g creatinine), slowed CKD progression, and reduced cardiovascular events but has not reduced progression to ESKD (74,77).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [77]
In the citing paper
“The IRMA-2 study showed that treatment with irbesartan, an ARB, was associated with a dose-dependent reduction in the risk of progression of CKD, with an almost 3-fold risk reduction with the highest dose (300 mg per day) at 2 years of followup.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [11]
In the citing paper
“This effect was independent of the blood pressure -lowering properties of irbesartan.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [11]
In the citing paper
“In this regard, it should be noted that in related studies in patients with type 1 and type 2 diabetes, 1,28,29 the benefits of captopril or irbesartan were not tested in the presence of concurrent calcium-channel-antagonist therapy.”
From Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy (2001) · cites this paper as [29]
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Pitt, B., Poole-Wilson, P. A., Segal, R., Martinez, F. A., Dickstein, K., Camm, A. J., Konstam, M. A., Riegger, G., Klinger, G. H., Neaton, J., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02213-3 · Cited by 1,961
The Effect of Age on Creatinine Clearance in Men: A Cross-sectional and Longitudinal Study
Rowe, J. W., Andres, R., Tobin, J. D., Norris, A. H., & Shock, N. W. (1976) · Journal of Gerontology · doi:10.1093/geronj/31.2.155 · Cited by 1,104
Gæde, P., Vedel, P., Parving, H.-H., & Pedersen, O. (1999) · The Lancet · doi:10.1016/s0140-6736(98)07368-1 · Cited by 981
Self-citationTatti, P., Pahor, M., Byington, R. P., Mauro, P. D., Guarisco, R., Strollo, G., & Strollo, F. (1998) · Diabetes Care · doi:10.2337/diacare.21.4.597 · Cited by 850
Ravid, M., Savin, H., Jutrin, I., Bental, T., Katz, B., & Lishner, M. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-118-8-199304150-00001 · Cited by 775
Research works printed but not linked: 9
- Parving H-H, Østerby R, Ritz E. Diabetic nephropathy. In: Brenner BM, ed. The kidney. 6th ed. Philadelphia: W.B. Saunders, 2000:1731-73.
- Hofman W, 1989, Lab Med, 13, 470
- Seelig HP, 1969, Z Klin Chem Klin Biochem, 7, 581
- Goldstein DE, 1986, Clin Chem, 32, B64
- 10.1001/jama.271.4.275 · doi:10.1001/jama.271.4.275 · Paper page
- 10.2307/2281868 · doi:10.2307/2281868 · Paper page
- Mantel N, 1959, J Natl Cancer Inst, 27, 719
- Agardh C-D, 1996, J Hum Hypertens, 10, 185
- Estacio RO, 2000, Diabetes Care, 23, B54
Cited by
Items 301–400 of 1,008
Ibsen, H., Olsen, M. H., Wachtell, K., Borch‐Johnsen, K., Lindholm, L. H., Mogensen, C. E., Dahlöf, B., Snapinn, S. M., Wan, Y., & Lyle, P. A. (2006) · Diabetes Care · doi:10.2337/diacare.29.03.06.dc05-1724 · Cited by 117
Harris, R., Donahue, K., Rathore, S. S., Frame, P., Woolf, S. H., & Lohr, K. N. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-138-3-200302040-00015 · Cited by 113
de Zeeuw, D., Ramjit, D. R., Zhang, Z., Ribeiro, A. B., Kurokawa, K., Lash, J. P., Chan, J. C. N., Remuzzi, G., Brenner, B. M., & Shahinfar, S. (2006) · Kidney International · doi:10.1038/sj.ki.5000326 · Cited by 141
Treatment of Cardiovascular and Renal Risk Factors in the Diabetic Hypertensive
Sowers, J. R., & Haffner, S. M. (2002) · Hypertension · doi:10.1161/01.hyp.0000042097.39655.b7 · Cited by 113
Diabetic kidney disease: act now or pay later
Atkins, R. C., & Zimmet, P. (2010) · Nature Reviews Nephrology · doi:10.1038/nrneph.2010.10 · Cited by 111
Diabetic nephropathy: landmark clinical trials and tribulations
Chan, G. C. W., & Tang, S. C. W. (2015) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfu411 · Cited by 117
“In addition, the effect of RAS blockade in reverting microalbuminuria may even persist after treatment withdrawal, as demonstrated in a substudy of the IRMA-2 (Irbesartan in Patients with Type 2 Diabetes and Micro-albuminuria) trial, suggesting possible glomerular structural normalization [37].”
BackgroundInfluentialWeil, E. J., Fufaa, G., Jones, L. I., Lovato, T., Lemley, K. V., Hanson, R. L., Knowler, W. C., Bennett, P. H., Yee, B., Myers, B. D., et al. (2013) · Diabetes · doi:10.2337/db12-1512 · Cited by 108
Williams, B. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.10.069 · Cited by 117
Comprehensive approach to diabetic nephropathy
Satirapoj, B., & Adler, S. G. (2014) · Kidney Research and Clinical Practice · doi:10.1016/j.krcp.2014.08.001 · Cited by 123
“In the stage of microalbuminuria, the Irbesartan in Patients with Type 2 Diabetes Microalbuminuria (IRMA 2) study showed that the ARB reduced progression to overt nephropathy by 70% in hypertensive type 2 diabetic patients during a 2-year follow-up period [78].”
BackgroundAnalysis of Metabolic Parameters as Predictors of Risk in the RENAAL Study
Appel, G. B., Radhakrishnan, J., Avram, M. M., DeFronzo, R. A., Escobar-Jimenez, F., Campos, M. M., Burgess, E., Hille, D. A., Dickson, T. Z., Shahinfar, S., et al. (2003) · Diabetes Care · doi:10.2337/diacare.26.5.1402 · Cited by 109
Intensive Integrated Therapy of Type 2 Diabetes
Gæde, P., & Pedersen, O. (2004) · Diabetes · doi:10.2337/diabetes.53.suppl_3.s39 · Cited by 108
American Diabetes Association (2002) · Diabetes Care · doi:10.2337/diacare.25.2007.s85 · Cited by 107
Haller, H. G., Viberti, G. C., Mimran, A., Remuzzi, G., Rabelink, T. J., Ritz, E., Rump, L. C., Ruilope, L. M., Katayama, S., Ito, S., et al. (2006) · Journal of Hypertension · doi:10.1097/01.hjh.0000202820.56201.e6 · Cited by 106
Satoh, M., Fujimoto, S., Arakawa, S., Yada, T., Namikoshi, T., Haruna, Y., Horike, H., Sasaki, T., & Kashihara, N. (2008) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfn357 · Cited by 106
Angiotensin II blockers in obstructive pulmonary disease: a randomised controlled trial
Andreas, S., Herrmann‐Lingen, C., Raupach, T., Lüthje, L., Fabricius, J. A., Hruska, N., Körber, W., Büchner, B., Criée, C.-P., Hasenfuss, G. P., et al. (2006) · European Respiratory Journal · doi:10.1183/09031936.06.00098105 · Cited by 112
Jandeleit-Dahm, K., & Cooper, M. E. (2002) · Current Opinion in Nephrology and Hypertension · doi:10.1097/00041552-200203000-00014 · Cited by 106
Chronic Kidney Disease in Diabetes
McFarlane, P. A., Cherney, D. Z. I., Gilbert, R. E., & Senior, P. A. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.11.004 · Cited by 143
Dihydropyridine Calcium Channel Antagonists in the Management of Hypertension
Epstein, B. J., Vogel, K., & Palmer, B. F. (2007) · Drugs · doi:10.2165/00003495-200767090-00005 · Cited by 105
What is the evidence that microalbuminuria is a predictor of cardiovascular disease events?
Yuyun, M. F., Adler, A. I., & Wareham, N. J. (2005) · Current Opinion in Nephrology and Hypertension · doi:10.1097/01.mnh.0000165895.90748.3b · Cited by 105
Savarese, G., Costanzo, P., Cleland, J. G. F., Vassallo, E., Ruggiero, D., Rosano, G., & Perrone-Filardi, P. (2013) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2013-9-2-188-200 · Cited by 104
Kendall, D. M., & Harmel, A. P. (2002) · PubMed · Cited by 132
Integrating albuminuria and GFR in the assessment of diabetic nephropathy
Jerums, G., Panagiotopoulos, S., Premaratne, E., & MacIsaac, R. J. (2009) · Nature Reviews Nephrology · doi:10.1038/nrneph.2009.91 · Cited by 116
New, J. P., Middleton, R., Klebe, B., Farmer, C., de Lusignan, S., Stevens, P. E., & O'Donoghue, D. J. (2007) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02075.x · Cited by 104
Svensson, M., Sundkvist, G., Arnqvist, H. J., Björk, E., Blohmé, G., Bolinder, J., Henricsson, M., Nyström, L., Torffvit, O., Waernbaum, I., et al. (2003) · Diabetes Care · doi:10.2337/diacare.26.10.2903 · Cited by 104
Use of Renin-Angiotensin System Blockade in Advanced CKD: An NKF-KDOQI Controversies Report
Weir, M. R., Lakkis, J. I., Jaar, B. G., Rocco, M. V., Choi, M. J., Kramer, H., & Ku, E. (2018) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2018.06.010 · Cited by 111
Kawarazaki, W., Nagase, M., Yoshida, S., Takeuchi, M., Ishizawa, K., Ayuzawa, N., Ueda, K., & Fujita, T. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2011070734 · Cited by 102
Low-grade albuminuria and cardiovascular risk: What is the evidence?
Schmieder, R. E., Schrader, J., Zidek, W., Tebbe, U., Paar, W. D., Bramlage, P., Pittrow, D., & Böhm, M. (2007) · Clinical Research in Cardiology · doi:10.1007/s00392-007-0510-3 · Cited by 108
Chronic kidney disease and diabetes
Pyram, R., Kansara, A., Banerji, M. A., & Loney‐Hutchinson, L. (2011) · Maturitas · doi:10.1016/j.maturitas.2011.11.009 · Cited by 119
Ruggenenti, P., Lauria, G., Iliev, I. P., Fassi, A., Ilieva, A. P., Rota, S., Chiurchiu, C., Barlovic, D. P., Sghirlanzoni, A., Lombardi, R., et al. (2011) · Hypertension · doi:10.1161/hypertensionaha.111.174474 · Cited by 103
“This effect could be explained by different mechanisms: (1) reduced need for concomitant treatment with drugs that may worsen insulin sensitivity, such as diuretics and -blockers22; (2) direct effects of ACE inhibition on insulin sensitivity;22 and (3) additional effect in the combined therapy group of manidipine-medi…”
BackgroundUhlig, K., Levey, A. S., & Sarnak, M. J. (2003) · Seminars in Dialysis · doi:10.1046/j.1525-139x.2003.16028.x · Cited by 102
Chronic Kidney Disease in Diabetes
McFarlane, P. A., Gilbert, R. E., MacCallum, L., & Senior, P. A. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.01.037 · Cited by 115
Melatonin: new insights on its therapeutic properties in diabetic complications
Pourhanifeh, M. H., Hosseinzadeh, A., Dehdashtian, E., Hemati, K., & Mehrzadi, S. (2020) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-020-00537-z · Cited by 115
Renin–Angiotensin System Blockade and Cardiovascular and Renal Protection
Hoogwerf, B. J. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.10.009 · Cited by 111
An extremely high dose of losartan affords superior renoprotection in the remnant model
Fujihara, C. K., Rodrigues, M. V., Malheiros, D. M. A. C., & Zatz, R. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00290.x · Cited by 100
Strippoli, G. F., Bonifati, C., Craig, M. E., Navaneethan, S. D., & Craig, J. C. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006257 · Cited by 265
Angiotensin Receptor Blockers: Pharmacology, Efficacy, and Safety
Taylor, A. A., Siragy, H. M., & Nesbitt, S. D. (2011) · Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2011.00518.x · Cited by 115
“The IRMA 2 Trial The Irbesartan Microalbuminuria Type 2 Diabetes Mellitus in Hypertensive Patients (IRMA 2) trial was a randomized double-blind investigation that examined the effect of two different doses of irbesartan, 150 mg and 300 mg daily, on changes in urinary protein excretion in hypertensive, type 2 diabetic…”
BackgroundThomopoulos, C., Parati, G., & Zanchetti, A. (2016) · Journal of Hypertension · doi:10.1097/hjh.0000000000001052 · Cited by 100
Perico, N., Remuzzi, G., Griffin, M. D., Cockwell, P., Maxwell, A. P., Casiraghi, F., Rubis, N., Peracchi, T., Villa, A., Todeschini, M., et al. (2023) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000000000189 · Cited by 116
Herrington, W. G., Judge, P. K., Grams, M. E., & Wanner, C. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01942-7 · Cited by 150
Böhm, M., Thoenes, M., Danchin, N., Bramlage, P., Puerta, P. L., & Volpe, M. (2007) · Journal of Hypertension · doi:10.1097/hjh.0b013e3282ef1c5f · Cited by 105
Oral Contraceptives, Angiotensin-Dependent Renal Vasoconstriction, and Risk of Diabetic Nephropathy
Ahmed, S. B., Hovind, P. H., Parving, H., Rossing, P. R., Price, D. A., Laffel, L. M., Lansang, M. C., Stevanovic, R. D., Fisher, N. D. L., & Hollenberg, N. K. (2005) · Diabetes Care · doi:10.2337/diacare.28.8.1988 · Cited by 101
Self-citationLong-Term Dual Blockade With Candesartan and Lisinopril in Hypertensive Patients With Diabetes
Andersen, N. H., Poulsen, P. L., Knudsen, S. T., Poulsen, S. H., Eiskjær, H., Hansen, K. W., Helleberg, K., & Mogensen, C. E. (2005) · Diabetes Care · doi:10.2337/diacare.28.2.273 · Cited by 99
Reil (2009) · Vascular Health and Risk Management · doi:10.2147/vhrm.s5207 · Cited by 103
The ACTIVE Steering Committee (2006) · American Heart Journal · doi:10.1016/j.ahj.2005.06.026 · Cited by 105
Bakris, G. L., Ruilope, L. M., Locatelli, F., Ptaszynska, A., Pieske, B. M., de Champlain, J., Weber, M. A., & Raz, I. (2007) · Kidney International · doi:10.1038/sj.ki.5002455 · Cited by 103
Recent advances in diabetic nephropathy
Marshall, S. M. (2004) · Postgraduate Medical Journal · doi:10.1136/pgmj.2004.021287 · Cited by 116
Angiotensin II Receptor Blockade: Is There Truly a Benefit of Adding an ACE Inhibitor?
Forclaz, A., Maillard, M. P., Nussberger, J., Brunner, H. R., & Burnier, M. (2003) · Hypertension · doi:10.1161/01.hyp.0000047512.58862.a9 · Cited by 103
Anand, S., Shivashankar, R., Ali, M. K., Kondal, D., Binukumar, B. K., Montez‐Rath, M. E., Ajay, V. S., Pradeepa, R., Deepa, M., Gupta, R., et al. (2015) · Kidney International · doi:10.1038/ki.2015.58 · Cited by 109
“Randomized control trials evaluating the use of renin-angiotensin-aldosterone system blockers to treat albuminuria in patients with diabetes mellitus (26) and/or hypertension (23) have shown a decrease in rates of progression of kidney disease.”
Vitamin D and diabetes mellitus: Causal or casual association?
Grammatiki, M., Rapti, E., Karras, S. Ν., Ajjan, R., & Kotsa, K. (2017) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-016-9403-y · Cited by 117
Albuminuria, not only a cardiovascular/renal risk marker, but also a target for treatment?
de Zeeuw, D. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.09201.x · Cited by 102
The Family Investigation of Nephropathy and Diabetes (FIND)
Knowler, W. C., Coresh, J., Elston, R. C., Freedman, B. I., Iyengar, S. K., Kimmel, P. L., Olson, J. M., Plaetke, R., Sedor, J. R., & Seldin, M. F. (2005) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2003.12.007 · Cited by 97
Lane, J. T. (2004) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00247.2003 · Cited by 106
Wang, J., Li, Y., Franklin, S. S., & Safar, M. E. (2007) · Hypertension · doi:10.1161/hypertensionaha.107.089763 · Cited by 105
Ruggenenti, P. L., Porrini, E., Motterlini, N., Perna, A., Parvanova, A. I., Iliev, I. P., Dodesini, A. R., Trevisan, R., Bossi, A. C., Sampietro, G., et al. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012030252 · Cited by 99
3: Preventing complications of diabetes
Bate, K. L., & Jerums, G. (2003) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2003.tb05655.x · Cited by 97
Present and future drug treatments for chronic kidney diseases: evolving targets in renoprotection
Perico, N., Benigni, A., & Remuzzi, G. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2685 · Cited by 108
de Jong, P. E., & Brenner, B. M. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.66001.x · Cited by 102
ACE2: A novel therapeutic target for cardiovascular diseases
Sarkissian, S. D., Huentelman, M. J., Stewart, J. M., Katovich, M. J., & Raizada, M. K. (2005) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2005.05.011 · Cited by 102
Urinary CCN2 (CTGF) as a possible predictor of diabetic nephropathy: Preliminary report
Riser, B. L., Cortés, P., DeNichilo, M. O., Deshmukh, P. V., Chahal, P. S., Mohammed, A. K., Yee, J., & Kahkonen, D. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00130.x · Cited by 94
Galle, J., Schwedhelm, E., Pinnetti, S., Böger, R. H., Wanner, C., & on behalf of the VIVALDI investigators (2008) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfn230 · Cited by 105
Agodoa, L. Y. C., & Eggers, P. W. (2007) · Seminars in Dialysis · doi:10.1111/j.1525-139x.2007.00350.x · Cited by 94
Angiotensin II Blockade Restores Albumin Reabsorption in the Proximal Tubules of Diabetic Rats
Tojo, A., Onozato, M. L., Kurihara, H., Sakai, T., Goto, A., & Fujita, T. (2003) · Hypertension Research · doi:10.1291/hypres.26.413 · Cited by 92
Prediction, progression and prevention of diabetic nephropathy. The Minkowski Lecture 2005
Rossing, P. R. (2005) · Diabetologia · doi:10.1007/s00125-005-0077-3 · Cited by 94
Heart Failure and Diabetes Mellitus: Epidemiology and Management of an Alarming Association
Solal, A. C., Beauvais, F., & Logeart, D. (2008) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2008.04.001 · Cited by 99
The clinical use of angiotensin-converting enzyme inhibitors
Wong, J. S., Patel, R. A., & Kowey, P. R. (2004) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2004.04.003 · Cited by 95
Hypertension and kidney disease: A deadly connection
Barri, Y. M. (2008) · Current Hypertension Reports · doi:10.1007/s11906-008-0009-y · Cited by 111
George, C., Echouffo-Tcheugui, J. B., Jaar, B. G., Okpechi, I. G., & Kengne, A. P. (2022) · BMC Medicine · doi:10.1186/s12916-022-02438-6 · Cited by 91
Mathur, R., Dreyer, G., Yaqoob, M. M., & Hull, S. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-020145 · Cited by 95
Taira, M., Toba, H., Murakami, M., Iga, I., Serizawa, R., Murata, S., Kobara, M., & Nakata, T. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.06.019 · Cited by 97
Palmer, A. J., Annemans, L., Roze, S., Lamotte, M., Lapuerta, P., Chen, R., Gabriel, S., Carita, P., Rodby, R. A., de Zeeuw, D., et al. (2004) · Diabetes Care · doi:10.2337/diacare.27.8.1897 · Cited by 93
Self-citationOta, T., Takamura, T., Ando, H., Nohara, E., Yamashita, H., & KOBAYASHI, K. P. (2003) · Diabetologia · doi:10.1007/s00125-003-1099-3 · Cited by 91
Metabolomics Approaches for the Diagnosis and Understanding of Kidney Diseases
Abbiss, H., Maker, G. L., & Trengove, R. D. (2019) · Metabolites · doi:10.3390/metabo9020034 · Cited by 98
Pedersen, O. B., & Gæde, P. (2003) · Metabolism · doi:10.1016/s0026-0495(03)00213-0 · Cited by 98
Microalbuminuria as a Target to Improve Cardiovascular and Renal Outcomes
Basi, S., & Lewis, J. D. (2006) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2006.02.182 · Cited by 98
Pathogenesis of Chronic Cardiorenal Syndrome: Is There a Role for Oxidative Stress?
Rubattu, S., Mennuni, S., Testa, M., Mennuni, M., Pierelli, G., Pagliaro, B., Gabriele, E., Coluccia, R., Autore, C., & Volpe, M. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms141123011 · Cited by 88
“both in diabetic and in nondiabetic patients [124–126].”
BackgroundHiremath, S. S., Fergusson, D. A., Fergusson, N. A., Bennett, A., & Knoll, G. A. (2016) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2016.08.018 · Cited by 93
de Faria, J. B. L., Silva, K. C., & de Faria, J. M. L. (2011) · Hypertension Research · doi:10.1038/hr.2010.263 · Cited by 95
Savoia, C., Touyz, R. M., Endemann, D. H., Pu, Q., Ko, E. A., De Ciuceis, C., & Schiffrin, E. L. (2006) · Hypertension · doi:10.1161/01.hyp.0000230234.84356.36 · Cited by 89
Diabetic Kidney Disease: Act Now or Pay Later
Atkins, R. C., & Zimmet, P. (2008) · Brazilian Journal of Transplantation · doi:10.1007/s00467-009-1400-x · Cited by 93
Causes and timing of end-stage renal disease after living kidney donation
Matas, A. J., Berglund, D. M., Vock, D. M., & Ibrahim, H. N. (2018) · American Journal of Transplantation · doi:10.1111/ajt.14671 · Cited by 87
Treatment approach to type 2 diabetes: Past, present and future
Blaslov, K., Naranđa, F. S., Kruljac, I., & Renar, I. P. (2018) · World Journal of Diabetes · doi:10.4239/wjd.v9.i12.209 · Cited by 113
Sarafidis, P. A., Stafylas, P. C., Kanaki, A. I., & Lasaridis, A. N. (2008) · American Journal of Hypertension · doi:10.1038/ajh.2008.206 · Cited by 87
A PAI-1 Mutant, PAI-1R, Slows Progression of Diabetic Nephropathy
Huang, Y., Border, W. A., Yu, L. H., Zhang, J., Lawrence, D. A., & Noble, N. A. (2008) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007040510 · Cited by 87
Lakshmanan, A. P., Watanabe, K., Thandavarayan, R. A., Sari, F. R., Harima, M., Giridharan, V. V., Soetikno, V., Kodama, M., & Aizawa, Y. (2011) · Free Radical Research · doi:10.3109/10715762.2011.560149 · Cited by 87
Diabetes and Cardiovascular Diseases
Kaur, J., Singh, P., & Sowers, J. R. (2002) · American Journal of Therapeutics · doi:10.1097/00045391-200211000-00009 · Cited by 97
Microalbuminuria: A parameter that has changed diabetes care
Parving, H., Persson, F., & Rossing, P. R. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.10.014 · Cited by 94
Self-citationGembillo, G., Ingrasciotta, Y., Crisafulli, S., Luxi, N., Siligato, R., Santoro, D., & Trifirò, G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094824 · Cited by 113
“These drugs played a pivotal role in reducing albuminuria and slowing GFR losses in several clinical trials, such as the Collaborative study (captopril) [69], RENAAL (losartan) [70], and the IRMA and IDNT studies (irbesartan) [71,72].”
BackgroundThe Growing Challenge of Chronic Kidney Disease: An Overview of Current Knowledge
Borg, R., Carlson, N., Søndergaard, J., & Persson, F. (2023) · International Journal of Nephrology · doi:10.1155/2023/9609266 · Cited by 149
Underuse of ACE Inhibitors and Angiotensin II Receptor Blockers in Elderly Patients With Diabetes
Winkelmayer, W. C., Fischer, M. A., Schneeweiß, S., Wang, P. S., Levin, R., & Avorn, J. (2005) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2005.08.018 · Cited by 91
Giorgino, F., Vora, J. P., Fenici, P., & Solini, A. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01163-9 · Cited by 95
Screening, identifying, and treating chronic kidney disease: why, who, when, how, and what?
Farrell, D. R., & Vassalotti, J. A. (2024) · BMC Nephrology · doi:10.1186/s12882-024-03466-5 · Cited by 114
“Patients with diabetes and moderate albuminuria (A2 or uACR 30-300 mg/g) benefit from maximally tolerated ACEi or ARB given trial data exhibiting decreased development of increasing albuminuria to A3 [80, 81].”
BackgroundDiabetic nephropathy: a disorder of oxygen metabolism?
Miyata, T., & de Strihou, C. V. Y. (2009) · Nature Reviews Nephrology · doi:10.1038/nrneph.2009.211 · Cited by 86
Angiotensin receptor blockers: Therapeutic targets and cardiovascular protection
Ruilope, L. M., Rosei, E. A., Bakris, G. L., Mancia, G., Poulter, N. R., Taddei, S., Unger, T., Volpe, M., Waeber, B., & Zannad, F. M. (2005) · Blood Pressure · doi:10.1080/08037050500230227 · Cited by 94
2010 Guidelines of the Taiwan Society of Cardiology for the Management of Hypertension
Chiang, C., Wang, T., Li, Y.-H., Lin, T., Chien, K., Yeh, H., Shyu, K., Tsai, W.-C., Chao, T.-H., Hwang, J., et al. (2010) · Journal of the Formosan Medical Association · doi:10.1016/s0929-6646(10)60120-9 · Cited by 90
Microalbuminuria: target for renoprotective therapy PRO
Roscioni, S. S., Heerspink, H. J. L., & de Zeeuw, D. (2014) · Kidney International · doi:10.1038/ki.2013.490 · Cited by 93
Insights into the mechanisms of renal fibrosis: is it possible to achieve regression?
Chatziantoniou, C., & Dussaule, J. (2005) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00453.2004 · Cited by 92
Chronic kidney disease: issues and establishing programs and clinics for improved patient outcomes
Peter, W. L. S., Schoolwerth, A. C., McGowan, T., & McClellan, W. M. (2003) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(03)00188-4 · Cited by 95
Mann, J. F. E., Gerstein, H. C., Yi, Q., Franke, J., Lonn, E., Hoogwerf, B. J., Rashkow, A. M., & Yusuf, S. (2003) · American Journal of Kidney Diseases · doi:10.1016/j.ajkd.2003.07.015 · Cited by 92
Tuttle, K. R., & Anderson, P. W. (2003) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(03)00741-8 · Cited by 91
Dussol, B., Iovanna, C., Raccah, D., Darmon, P., Morange, S., Vague, P., Vialettes, B., Oliver, C., Loundoun, A., & Berland, Y. (2005) · Journal of Renal Nutrition · doi:10.1053/j.jrn.2005.07.003 · Cited by 84
Metadata
- Authors
- Parving, H.-H., Lehnert, H., Bröchner-Mortensen, J., Gomis, R., Andersen, S., & Arner, P.
- Affiliations
- Steno Diabetes Center Copenhagen (DK)
- University Hospital Magdeburg (DE)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2001-09-20
- Volume
- 345
- Issue
- 12
- Pages
- 870-878
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2003670762
- Semantic Scholar
- bec1f00c2120232a55a25b7d846d63e92a3ff8fc
- Cited by
- 2,873
- References
- 26
- Citations by year
- 2026: 30 · 2025: 44 · 2024: 50 · 2023: 61 · 2022: 61 · 2021: 58 · 2020: 63 · 2019: 50 · 2018: 63 · 2017: 71 · 2016: 84 · 2015: 88 · 2014: 105 · 2013: 103 · 2012: 117
- FWCI
- 146.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Nephrology › Renal Diseases and Glomerulopathies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Keywords
- irbesartan, diabetic nephropathy, type 2 diabetes, hypertension, microalbuminuria, renal protection, angiotensin receptor blockers, renin-angiotensin system blockade, albuminuria, blood pressure, dose comparison, adverse events, renin-angiotensin system inhibitors
- MeSH terms
- Irbesartan, Adult, Aged, Albuminuria, Antihypertensive Agents, Biphenyl Compounds, Creatinine, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Double-Blind Method, Female, Humans, Hypertension, Male, Middle Aged, Tetrazoles, Proportional Hazards Models, Disease Progression, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.